Logo

AxoGen, Inc.

AXGN

AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucos… read more

Healthcare

Medical Devices

39 years

USD

Exclusive to Premium users

Price

per share adjusted in USD

$40.93

Price

+0.34%

$0.14

Market Cap

$2.177b

Mid

Price/Earnings

-

Premium

3y Avg

Premium

5y Avg

Financial Reports

Key metrics over the past few years and other important metrics. Amounts in USD.

-4.6%

EBITDA Margin

-31.9%

Net Profit Margin

-2.0%

Free Cash Flow Margin

-4.6%

EBITDA Margin

-31.9%

Net Profit Margin

-2.0%

Free Cash Flow Margin
Revenue

$238.105m

+5.7%

1y CAGR

+14.6%

3y CAGR

+14.6%

5y CAGR
Earnings

-$31.453m

-100.3%

1y CAGR

-34.6%

3y CAGR

-19.7%

5y CAGR
EPS

-$0.63

-85.3%

1y CAGR

-26.1%

3y CAGR

-13.0%

5y CAGR
Book Value

$244.808m

$289.488m

Assets

$44.680m

Liabilities

$20.642m

Debt
Debt to Assets

7.1%

3.6x

Debt to EBITDA
Free Cash Flow

$8.933m

+404.6%

1y CAGR

-8753.0%

3y CAGR

-6553.6%

5y CAGR
No items found.
Press Releases
Statements and updates from the company
↑ TopSummaryPriceFinancialsPress Releases